Abstract:Background & aims: MRI biomarkers of liver disease are robust and reproducible alternatives to liver biopsy. Emerging data suggest that absolute reduction in iron-corrected T1 (cT1) of ≥80 ms and relative reduction in liver fat content of 30% reflect histological improvement. We aimed to validate the associations of changes to these non-invasive biomarkers with histological improvement, specifically the resolution of steatohepatitis. Methods: We performed a retrospective analysis of participants from three interventional clinical trials who underwent multiparametric MRI to measure liver cT1 and liver fat content (LFC) (LiverMultiScan) alongside biopsies at baseline and end of study. Responders were defined as those achieving resolution of steatohepatitis with no worsening in fibrosis. Differences in the magnitude of change in cT1 and LFC between responders and non-responders were assessed. Results: Individual patient data from 150 participants were included. There was a significant decrease in liver cT1 (-119 ms vs. -49 ms) and LFC (-65% vs. -29%) in responders compared to non-responders (p <0.001), respectively. The diagnostic accuracy to identify responders was 0.72 (AUC) for both. The Youden's index for cT1 to separate responders from non-responders was -82 ms and for liver fat was a 58% relative reduction. Those achieving a ≥80 ms reduction in cT1 were 5-fold more likely to achieve histological response (sensitivity 0.68; specificity 0.70). Those achieving a 30% relative reduction in liver fat were ∼4-fold more likely to achieve a histological response (sensitivity 0.77; specificity 0.53). Conclusions: These results, from a pooled analysis of three drug trials, demonstrate that changes in multiparametric MRI markers of liver health (cT1 and LFC) can predict histological response for steatohepatitis following therapeutic intervention. Impact and implications: We investigated the utility of two MRI-derived non-invasive tests, iron-corrected T1 mapping (cT1) and liver fat content from proton density fat fraction (PDFF), to predict histological improvement in patients who had undergone experimental treatment for metabolic dysfunction-associated steatohepatitis. Using data from 150 people who participated in one of three clinical trials, we observed that a reduction in cT1 by over 80 ms and a relative reduction in PDFF of over 58% were the optimal thresholds for change that predicted resolution of steatohepatitis on histology. PDFF as a marker of liver fat, and cT1 as a specific measure of liver disease activity, are both effective at identifying those who are likely responding to drug interventions and experiencing improvements in overall liver health. Clinical trial number(s): NCT02443116, NCT03976401, NCT03551522.

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis

Accuracy of Non‐Invasive Imaging Techniques for the Diagnosis of MASH in Patients With MASLD: A Systematic Review

Diagnostic accuracy of non‐invasive tests to screen for at‐risk MASH—An individual participant data meta‐analysis

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

Analytical and Clinical Validation of AIM-NASH: A Digital Pathology Tool for Artificial Intelligence-based Measurement of Nonalcoholic Steatohepatitis Histology

Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction‐associated steatohepatitis

Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH

Positron emission tomography combined with serum biomarkers detects fibrotic MASH

Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis

FibroScan‐AST score for diagnosing fibrotic MASH: A systematic review and meta‐analysis of diagnostic test accuracy studies

Quantitative MRI for Monitoring Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Test–Retest Repeatability Study

Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH

One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning

A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease

An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis

AI-based Digital Pathology Provides Newer Insights into Lifestyle Intervention-Induced Fibrosis Regression in MASLD: an Exploratory Study.

Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model